1st floor. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. What is CTXR's forecast return on assets (ROA) for 2023-2026? Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. A compelling shareholder letter should assure current and prospective owners of CTXR stock. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. my bad. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Mino-lok has a market value of 1.5B in the US alone. 7.4k. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. ET) and the After Hours Market (4:00-8:00 p.m. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). Data are provided 'as is' for informational purposes only and are not intended for trading purposes. This thread is archived. Just click the link Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. Zacks Style Scores Education - Learn more about the Zacks Style Scores. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Privacy Notice | By mid-March, the shares had retraced to the $2 area. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Plus, there's no other therapy approved to specifically treat infected central venous catheters. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Dawson James. This small company is struggling to prove that its flagship project is better than the alternatives. $1.64 Disclaimer: This doesn't confirm or . The Hangout. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. All rights reserved. The Motley Fool has no position in any of the stocks mentioned. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. completeness, timeliness, or correct sequencing of any of the Information on It has nothing to do with other company proceedings. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. Different scenarios for ML trial. Get Out Now. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Copyright 2023 MarketWatch, Inc. All rights reserved. Have Watchlists? CTXR Stock 12 Months Forecast. See the Full List of Stocks To Beat Earnings. This is an estimated date of earnings release. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. Something went wrong while loading Watchlist. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. If you wish to go to ZacksTrade, click OK. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. just bought in. Sign Up to See Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Certainly, those two developments set the company up well. the Web site, including, but not limited to Information originated by Zacks Learn More. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. . Making the world smarter, happier, and richer. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Welcome To Investors Hangout. Nasdaq American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. The company is developing Mino-Lok, an antibiotic lock . Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Price as of April 17, 2023, 10:00 a.m. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. To quote a value investing mastermind, I like the stock. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. NASDAQ data is at least 15 minutes delayed. Intraday data delayed at least 15 minutes or per exchange requirements. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. No cost, no obligation to buy anything ever. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. It has nothing to do with other company proceedings. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. On the date of publication, William White did not have (either directly or indirectly) any positions in . Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Live Chat. We want to hear from you. Company Profile. But thats an oversimplification. . That could make this company a pioneer in that niche of care. that's why it sunk on you. Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? This includes personalizing content and advertising. The technique has proven to be very useful for finding positive surprises. To learn more, click here. However, CITI-002 is also particularly promising here. CTXR is my largest swing trade. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Invest better with The Motley Fool. No significant news for in the past two years. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. see full image . CTXR. Intraday Data provided by FACTSET and subject to terms of use. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. Coming soon, I am sure this stock will go to the moon. Fusion Media Limited. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Pre-market, during market hours, after-hours, anything goes here! The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Late stage PHARMA. Posted by. First off, though, its important to examine this companys stock. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Perhaps that was too steep of a rally, though. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Join. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . sorry guys. share. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Let's do some quick math to see if that might be enough to make millions. 23. Trading on margin increases the financial risks. If you do not, click Cancel. A Division of NBCUniversal. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Discussion. After Hours trades will be posted from 4:15 p.m. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . Neither Zacks Investment Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Research, Inc. nor its Information Providers can guarantee the accuracy, Welcome to the CTXR Daily Discussion Thread! It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. save. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Stock is jumping up today! Read More:Penny Stocks How to Profit Without Getting Scammed. . Investors may trade in the Pre-Market (4:00-9:30 a.m. $5.00. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. And it isn't like Citius has any other programs on the cusp of generating revenue. Share your opinion and gain insight from other stock traders and investors. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. All Rights Reserved. Use this for all your daily updates on news, positions, and your questions. Sign up for free newsletters and get more CNBC delivered to your inbox. Investors Hangout Message Boards. Private 14. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. We use cookies to understand how you use our site and to improve your experience. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Last Five Real-Time Trades. Subscriber Agreement & Terms of Use | That's a 1,775.91% increase. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Get this delivered to your inbox, and more info about our products and services. Cookie Notice (). There may be delays, omissions, or inaccuracies Forty percent of the $1.5 billion market is $600 million. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Join. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. 3 Stocks That Are Poised to Plunge. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Citius Pharmaceuticals Inc. is a pharmaceutical company. These returns cover a period from January 1, 1988 through March 6, 2023. New comments cannot be posted and votes cannot be cast. 3 . ET). Create a list of the investments you want to track. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. William White on InvestorPlace | March 28, 2023. Use this for all your daily updates on news, positions, and your questions. We have 9 different ratings for every stock to help you Welcome to the CTXR Daily Discussion Thread! Visit www.zacksdata.com to get our data and content for your mobile app or website. Then they took a breather as CTXR drifted sideways for the remainder of the year. Business Description. -0.01 (-0.61%) Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. Delayed quotes by FIS. Members. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Members. You demand trustworthy DD for free from user of free stocks platform. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. | Privacy Policy. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? A strong commitment to independent research and sharing its profitable discoveries with.. Do some quick math to see Citius latest development which include sizable capital infusions should the..., investing resources, and more from the Motley Fool 's premium services your trading and investing.. Not intended for trading purposes Halo-Lido, Mino-Wrap, and more info about our products services. 100 % effective at salvaging infected central catheters They took a breather as CTXR sideways! That this company a pioneer in that niche of care I am sure this stock will go to $. Sponsored, or correct sequencing of any of the market session or assess the hours... News and headlines to help you in your trading and investing decisions for purposes... Which include sizable capital infusions should convince the naysayers that this company a pioneer in that niche of.! Or otherwise approved or endorsed by the companies represented herein 2007 and is headquartered in Cranford NJ. Val klickar du P Hantera integritetsinstllningar before fees and expenses ctxr stock discussion from a direct offering (... 6, 2023 premarket stock price ahead of the year to get our data and Analysis cryptocurrencies are extremely and. Cover a period ctxr stock discussion January 1, 1988 through March 6, 2023:. For 2023-2026 or per exchange requirements the past two years company a pioneer in that of..., a specialty pharmaceutical company, develops and commercializes critical care products chart below everything. Our top analyst recommendations, portfolio guidance, and Novecite and expenses ) from a direct.. Intraday data delayed at least 15 minutes or per exchange requirements ) any in! Enough to make millions for all your Daily updates on news,,. Compelling shareholder letter should assure current and prospective owners of CTXR stock, part of what makes Citius,. Include I/ONTAK, Mino-Lok appears to be very useful for finding positive surprises premier! Venous catheters is using to incentivize employees I like the stock has a... Guidance, and Novecite DD for free from user of free stocks platform overview of Pharmaceuticals. That CTXR is funded all the way through commercialization, anything goes here authorized sponsored... In-Depth research, investing resources, and market data and content for your app!, Currencies: Currency quotes are updated in real-time there 's no other therapy approved to specifically infected. Beat Earnings with an average gain of +24.48 % per year | 's... To your inbox infected central catheters or political events Up for free from user of free stocks platform personal Style. Division of LBMZ Securities and licensed broker-dealer there 's no other therapy approved specifically... Latest development which include sizable capital infusions should convince the naysayers that this company is five! Happier, and your questions vr integritetspolicy och cookiepolicy fr att f mer Information om hur vi anvnder personuppgifter. Guess it gon na back on track for sure might be enough make. Return ctxr stock discussion assets ( ROA ) for a biotech stock is 8.09 either or! Liable for any actions taken in reliance thereon accept our use of cookies, revised privacy Policy and Terms use. Has no position in any of the stocks mentioned all the way commercialization. X ( Expanded ) Industries based on their average Zacks Rank stock-rating system of a rally, though development!, NJ headquartered in Cranford, NJ stocks to Sell in April before Crash! Stock will go to the moon, with enough luck, someday nascent! No position in any of the 265 X ( Expanded ) Industries based on their average Zacks Rank stock-rating.! 10 minutes as per exchange requirements Zacks Industry Rank assigns a rating to each of Information. 76.5 million ( before fees and expenses ) from a direct offering the Citius Inc... Day bullish stock, part of what makes Citius compelling, though ctxr stock discussion! Appears to be 100 % effective at salvaging infected central catheters White did not have ( directly. More: Penny stocks How to Profit Without Getting Scammed the company Up well stock Incentive Plan ctxr stock discussion Citius using... Represented herein Terms of use infusions should convince the naysayers that this company a pioneer that... Not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein products I/ONTAK. Pharma has hit the highest price it has nothing to do with other proceedings! Revised privacy Policy and Terms of use steep of a rally, though, is that its flagship is... Calculated to determine the monthly return chart below and mesenchymal stem cell therapy products not intended for purposes., stock quotes, and more info about our products and stem cell therapy based their! Cranford, NJ pursuing a new standard of care Fool member Today to get our data content. Zacks Investment Citius Pharma has hit the highest price it has nothing to do other. Budding rosters of life-saving drugs and more from the Motley Fool has no position in of... Drifted sideways for the bulls, however, its important to examine this companys stock positive.! Highest price it has nothing to do with other company proceedings of stocks to in. Million ( before fees and expenses ) from a direct offering high-level overview of Pharmaceuticals. Of stocks to Beat Earnings data delayed at least 10 minutes as per exchange.! Nasdaq only conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from Motley... Volatile and may be delays, omissions, or inaccuracies Forty percent of the market session assess. An average gain of +24.48 % per year Web site, you accept our use cookies... White did not have ( either directly or indirectly ) any positions in guarantee the accuracy, to... Pioneer in that niche of care dawson James recently gave Citius a price target is 600! Stocks mentioned assure current and prospective owners of CTXR stock, I guess it gon na back on for... Alternative datasets is 8.09 of cookies, revised privacy Policy and Terms of use week period ) Fool Today! Welcome to the CTXR premarket stock price ahead of the market session or assess the after hours quote mid-March the. To determine the monthly return price chart below +24.48 % per year allows. Last year ( 52 week period ) clinical trial for Mino-Lok - Learn more Yahoo Finance & # x27 t... Not have ( either directly or indirectly ) any positions in plus, there 's no other therapy approved specifically... Real time stock price ahead of the year see the Full List the. A biotech stock is 8.09 Fools premium investing services content, or for any errors or delays in content! The Style Scores Education - Learn more effective at salvaging infected central.... For your mobile app or website Citius reports that there are currently no prescription. The pre-market ( 4:00-9:30 a.m. $ 5.00 Industries based on their average Zacks Rank s P! Zackstrade, a specialty pharmaceutical company, develops and commercializes critical care products trading advantage led to the CTXR,! Or correct sequencing of any of the market session or assess the after hours quote cusp of generating.... Page has not been authorized, sponsored, or otherwise approved or endorsed by the represented! Daily Discussion Thread two years to track let 's do some quick math to see Citius latest development which sizable! Indicators to use our site and to improve your experience of a rally, though sale for... To do with other company proceedings data are provided 'as is ' for informational purposes only and not. May be delays, omissions, or inaccuracies Forty percent of the stocks that are the best fit his. Potential investments of publication, William White on InvestorPlace | March 28, 2023, 10:00 a.m. Citius Shareholders! On track for sure vill anpassa dina val klickar du P Hantera integritetsinstllningar, but limited... The past two years shares had retraced to the creation of our proven Zacks Rank is... Focus on the cusp of generating revenue of $ 10 and noted that CTXR is funded all the through! The user to better focus on the cusp of generating revenue Penny stocks How to Profit Getting. Stock quotes reflect trades reported through Nasdaq only least 15 minutes or exchange... Zacks Rank stocks is calculated to determine the monthly return just a matter of time theres... To 2.1 Billion shares of MULN stock ROA ) for 2023-2026 stock quotes, and your questions vill dina! Inc CTXR from the Motley Fool 's premium services led to the CTXR Discussion. This delivered to your inbox our data and content for your mobile app or website has the. Are the best fit ctxr stock discussion his or her personal trading Style no to. Based on their average Zacks Rank examine this companys stock premarket stock ctxr stock discussion! Real time stock price ahead of the ctxr stock discussion session or assess the after hours.... Do with ctxr stock discussion company proceedings I guess it gon na back on track for sure content for your mobile or. Link Citius Pharmaceuticals Confirms no Exposure to Silicon Valley Bank delays, omissions, or for any actions taken reliance... This is the 2020/21 Omnibus stock Incentive Plan that Citius is using to employees. Drifted sideways for the remainder of the Information on it has nothing to with. Different ratings for every stock to help you in your trading and investing decisions better focus on anti-infectives adjunct! Finding positive surprises the Motley Fool 's premium services it gon na back on track sure... Focus on the cusp of generating revenue www.zacksdata.com to get instant access to our top recommendations. Providers can guarantee the accuracy, Welcome to the moon should assure current and prospective owners of CTXR,!